Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
The purpose of this study is to find the highest dose of the investigational drug RLY-2608 that can be used alone in people with advanced solid tumors and with fulvestrant in people with advanced breast cancer. Participants in this study will have cancers that contain a mutation in a gene called PIK3CA. Their cancers must have continued to grow despite treatment or be inoperable.
Researchers are doing this study to find the best dose of ziftomenib to give with standard chemotherapy in children and young adults with acute leukemia. The people in this study have acute leukemia that keeps growing or came back after treatment. In addition, their cancers have a mutation (change) in the KMT2A, NUP98, or NPM1 genes.
Umbilical card blood is rich in healthy, blood-forming cells (stem cells) that are very good at fighting blood cancers. Cord blood transplants (CBT) are a standard treatment for adults with blood cancers who lack a genetically matched stem cell donor. Cord blood is donated by a baby's mother at birth. CBT uses stem cells from cord blood collections to replace cells that have been destroyed by disease or anti-cancer treatment.
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
Ruxolitinib is used to treat myelofibrosis, a rare bone marrow cancer that disrupts your body's normal blood cell production. Some people taking this drug, however, keep having symptoms. Researchers want to see if adding the drug ulixertinib to ruxolitinib treatment is safe and works better to treat myelofibrosis.
Researchers are comparing two new combination drug treatments with the standard therapy for multiple myeloma. The people in this study have multiple myeloma that is newly diagnosed. In addition, they cannot have an autologous stem cell transplant with high-dose chemotherapy.
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
The purpose of this study is to find the highest dose of the investigational drug NVL-655 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that contain a genetic change called an ALK gene fusion. NVL-655 is a type of drug called a tyrosine kinase inhibitor (TKI), which works by blocking proteins that fuel cancer growth. However, some cancer cells develop resistance to TKI treatment.
Researchers are assessing the combination of sacituzumab govitecan and cetuximab for treating head and neck cancer. The people in this study have squamous cell cancer of the head and neck. Their cancer came back or spread after prior treatment.
